2',5,7-Trihydroxy-8-methoxyflavanoneCAS# 112408-71-6 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 112408-71-6 | SDF | Download SDF |
PubChem ID | 13889012 | Appearance | Powder |
Formula | C16H14O6 | M.Wt | 302.3 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S)-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-methoxy-2,3-dihydrochromen-4-one | ||
SMILES | COC1=C(C=C(C2=C1OC(CC2=O)C3=CC=CC=C3O)O)O | ||
Standard InChIKey | URBNKMKLIWQQRO-ZDUSSCGKSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 2',5,7-Trihydroxy-8-methoxyflavanone has cytotoxic activity. |
2',5,7-Trihydroxy-8-methoxyflavanone Dilution Calculator
2',5,7-Trihydroxy-8-methoxyflavanone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.308 mL | 16.5399 mL | 33.0797 mL | 66.1594 mL | 82.6993 mL |
5 mM | 0.6616 mL | 3.308 mL | 6.6159 mL | 13.2319 mL | 16.5399 mL |
10 mM | 0.3308 mL | 1.654 mL | 3.308 mL | 6.6159 mL | 8.2699 mL |
50 mM | 0.0662 mL | 0.3308 mL | 0.6616 mL | 1.3232 mL | 1.654 mL |
100 mM | 0.0331 mL | 0.1654 mL | 0.3308 mL | 0.6616 mL | 0.827 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3'-Deoxy-4-O-methylsappanol
Catalog No.:BCN3675
CAS No.:112408-68-1
- 3-Deoxysappanchalcone
Catalog No.:BCN3736
CAS No.:112408-67-0
- Tetramethylpyrazine
Catalog No.:BCN1008
CAS No.:1124-11-4
- XL765
Catalog No.:BCC2060
CAS No.:1123889-87-1
- DMPQ dihydrochloride
Catalog No.:BCC6977
CAS No.:1123491-15-5
- WAY-262611
Catalog No.:BCC5507
CAS No.:1123231-07-1
- BRL 52537 hydrochloride
Catalog No.:BCC6751
CAS No.:112282-24-3
- H-Asp(OcHex)-OH
Catalog No.:BCC2887
CAS No.:112259-66-2
- 20(R)-Ginsenoside Rh2
Catalog No.:BCN2484
CAS No.:112246-15-8
- (S)-tert-Leucinol
Catalog No.:BCN8367
CAS No.:112245-13-3
- Stigmastane-3,6-diol
Catalog No.:BCN6003
CAS No.:112244-29-8
- 16-O-Methyl-14,15-didehydroisovincanol
Catalog No.:BCN1618
CAS No.:112237-71-5
- Ganoderic acid TN
Catalog No.:BCN2443
CAS No.:112430-64-5
- Ganoderic acid T-Q
Catalog No.:BCN3209
CAS No.:112430-66-7
- Ganoderic acid Jb
Catalog No.:BCN7972
CAS No.:112430-68-9
- AZ3146
Catalog No.:BCC3731
CAS No.:1124329-14-1
- 3-Phenyl-1-(pyrrol-1-yl)propan-1-one
Catalog No.:BCN4005
CAS No.:112448-69-8
- U-54494A hydrochloride
Catalog No.:BCC6668
CAS No.:112465-94-8
- H-Glu(OcHex)-OH
Catalog No.:BCC2929
CAS No.:112471-82-6
- 4,4-Pentamethylenepiperidine hydrochloride
Catalog No.:BCC6059
CAS No.:1125-01-5
- 5-Aminoisoquinoline
Catalog No.:BCC8736
CAS No.:1125-60-6
- 6-Aldehydo-isoophiopogonone A
Catalog No.:BCN6629
CAS No.:112500-90-0
- Aristolactam FI
Catalog No.:BCN6005
CAS No.:112501-42-5
- Picrasidine S
Catalog No.:BCN6006
CAS No.:112503-87-4
Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.[Pubmed:28987606]
Eur J Med Chem. 2017 Nov 10;140:448-464.
A series of novel berberine derivatives, 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines was designed, synthesized, and biologically evaluated for their anti-diabetic activity. Following the evaluation in two types of cells, compounds 4aa, 4bq, and 4bv stimulated glucose consumption (1.8- to 2.3-fold), reduced gluconeogenesis (60-85%), inhibited mitochondria respiratory chain complex I and activated AMPK indirectly. In a db/db mice model, compounds 4bq and 4bv lowered fasting blood glucose at a dose of 120 mg/kg/day. In addition, compounds 4bq and 4bv were found to possess improved pharmacokinetic profiles (bioavailability 45 and 106%, respectively) compared to berberine. Compounds 4bq and 4bv exhibited no obvious hERG inhibition (IC50 > 10 muM).
Control of alpha/beta Anomer Formation by a 2',5' Bridge: Toward Nucleoside Derivatives Locked in the South Conformation.[Pubmed:28972760]
J Org Chem. 2017 Nov 3;82(21):11337-11347.
We describe a novel stereoselective synthesis of nucleoside derivatives with the ribose ring locked in the South conformation by a bridge between C2' and C5'. Despite the intrinsic constraints of the bicyclic structure, we demonstrate that their synthesis can be achieved by ring closing metathesis of readily accessible precursors. The obtained ribose derivatives are, however, very poor substrates for further installation of the nucleobases, and even simple nucleophiles, such as azido or cyano anions, react with unexpected stereo- or regioselectivity under standard glycosylation conditions. Here we explain this behavior by employing density functional theory (DFT) computations and devise an alternative approach resulting in isomers with the desired orientation of the nucleobase.
Carborane-linked 2'-deoxyuridine 5'-O-triphosphate as building block for polymerase synthesis of carborane-modified DNA.[Pubmed:29017785]
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4786-4788.
5-[(p-Carborane-2-yl)ethynyl]-2'-deoxyuridine 5'-O-triphosphate was synthesized and used as a good substrate in enzymatic construction of carborane-modified DNA or oligonucleotides containing up to 21 carborane moieties in primer extension reactions by DNA polymerases.
Triplex- and Duplex-Forming Abilities of Oligonucleotides Containing 2'-Deoxy-5-trifluoromethyluridine and 2'-Deoxy-5-trifluoromethylcytidine.[Pubmed:28966282]
Chem Pharm Bull (Tokyo). 2017;65(10):982-988.
A facile synthesis of 2'-deoxy-5-trifluoromethyluridine and 2'-deoxy-5-trifluoromethylcytidine phosphoramidites from commercially available 2'-deoxyuridine and 2'-deoxycytidine was achieved, respectively. The obtained phosphoramidites were incorporated into oligonucleotides, and their binding affinity to double-stranded DNA (dsDNA) and single-stranded RNA (ssRNA) was evaluated by UV-melting experiments. The triplex-forming abilities of oligonucleotides including 5-trifluoromethylpyrimidine nucleobases with dsDNA were decreased. Especially, the stability of the triplex containing a trifluoromethylcytosine ((CF3)C)-GC base triplet was low, likely due to the low pKa of protonated (CF3)C by the electron-withdrawing trifluoromethyl group. A slight decrease in stability of the duplex formed with ssRNA by oligonucleotides including 5-trifluoromethylpyrimidine nucleobases was only observed, suggesting that they might be applicable to various ssRNA-targeted technologies using features of fluorine atoms.